News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Deals
Roche Seen Sealing Genentech, Inc. Deal After Upping Bid
March 9, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH (Reuters) - Roche Holding AG (VTX:ROG.VX - News) looks likely to seal a deal to buy out U.S. biotech group Genentech Inc (NYSE:DNA - News), analysts said on Monday, after the Swiss drugmaker upped its offer to $45.7 billion.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Europe
Genentech, Inc.
Roche
MORE ON THIS TOPIC
Cancer
Boehringer Ingelheim bets up to $1B in AI-centered solid tumor collab with Envisagenics
September 22, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
Western licensing deals for Chinese radioligand therapies to jump in 2027, Sleuth forecasts
September 21, 2026
·
2 min read
·
Nick Paul Taylor
C-suite
Novo’s plan to hit $23B in revenue by 2035 leaves investors wanting
September 21, 2026
·
5 min read
·
Annalee Armstrong
Mergers & acquisitions
Telix buys ITM for $1.65B in ‘supercritical’ radiopharma M&A
September 21, 2026
·
3 min read
·
Tristan Manalac
